Open AccessMYD88 Gene Polimorphism in Patients With Chronic Lenfoid Leukemia
Author(s) -
N. Irem Tiryaki-Yikrik,
Mehmet Özaslan,
Sibel Bayil-Oguzkan,
Mehmet Yılmaz
Publication year - 2021
Publication title -
the eurasia proceedings of health, environment and life sciences
Language(s) - English
Resource type - Journals
ISSN - 2791-8033
DOI - 10.55549/ephels.5
Subject(s) - genotype , chronic lymphocytic leukemia , exact test , allele , leukemia , bone marrow , lymph , immunology , statistical significance , cancer , medicine , allele frequency , gastroenterology , oncology , biology , gene , pathology , genetics
Leukemia is a type of cancer that manifests itself with the excessive proliferation of blood cells, especially white blood cells, and affects the blood production system in the body. Leukemias are classified as acute or chronic and according to the extent and development of the tumor. In chronic lymphocyte leukemia (CLL), cancer cells are found in the bone marrow, blood, and lymph nodes. Therefore, in this study, the effects of polymorphisms in the MYD88 gene of CLL patients were investigated. For this purpose, 100 patients diagnosed with CLL and 70 healthy individuals without cancer history were included in the study as the control group. DNA was isolated from CLL patients and control groups. Polymorphisms in the MYD88 (L265p T/C) promoter regions were studied by RT-PCR. Genotype and allele frequencies were calculated directly. Statistical significance of genotypic distributions between CLL patients and control groups was evaluated with Z Ratios test and Fisher's Exact test.For the MYD88 L265p T/C region in 100 CLL patients, 95 wild type TT, 3 TC and 5 mutant type CC genotypes were detected. No statistically significant difference was found between CLL patients and control groups in the MYD88 L265p T/C region (p 0.05). According to the allele frequencies of the region, it was determined as 0.965 and 0.065 for T and C, respectively. According to Fisher's Exact results, it was calculated as 0.078 for TT, 0.078 for TC and 0.269 for Mutant, respectively. The MYD88 genotype frequencies of the patients included in the study do not appear to be statistically correlated with CLL patients. The research we have done as a result of our study will shed light on the studies with different SNPs to be made with the increase in the number of CLL patients..